M/24/010 – Exponent/Chanelle HoldCo 3 Limited
Transaction details
The proposed acquisition by Exponent Private Equity LLP through its subsidiary Herriot Pharma Bidco Limited of the entire issued share capital and thus sole control of Chanelle HoldCo 3 Limited has been cleared by the Competition and Consumer Protection Commission.
| Notification date | Decision date |
|---|---|
| Tuesday February 13, 2024 | Thursday, February 29, 2024 |
| Parties Involved | Business activities |
|---|---|
| Exponent Private Equity LLP | Exponent Private Equity LLP is an international private equity group based in the United Kingdom which makes investments in businesses in the State, the UK and across Europe. |
| Herriot Pharma Bidco Limited | Herriot Pharma Bidco Limited is a limited liability company. Herriot Pharma Bidco Limited is a subsidiary of Exponent Private Equity LLP. |
| Chanelle HoldCo 3 Limited | Chanelle HoldCo 3 Limited is a direct subsidiary of Chanelle Pharma Limited. Chanelle HoldCo 3 Limited specialises in the development, registration, manufacture, wholesale, distribution, out-license, commercialisation and supply of both human and veterinary generic pharmaceutical products. |
| Economic sector | Media merger |
|---|---|
| Healthcare | No |
| Submissions from third parties due by: | |
|---|---|
| Phase 1 | Phase 2 |
| Monday, February 26, 2024 | |
| Current status: Completed |
|---|
| Cleared (Phase 1) |
| Authorised Officer Assigned | Contact Details |
|---|---|
| Éadaoin Burns | eadaoinburns@ccpc.ie |
Media enquiries: communications@ccpc.ie
Haven’t found what you’re looking for?
Competition and Consumer Protection Commission
PO Box 12585, Dublin 1, D01 C576
Tel +353 (0)1 402 5500
Consumer helpline 01 402 5555